What Studies Show About Staying on Zepbound for Maintenance and Switching to Foundayo

A common question in weight management is what happens after the initial weight loss phase. Once someone has lost weight on Zepbound, should they stay on it for maintenance? Can they step down to a lower dose? And what happens if they switch from Zepbound to Foundayo? Recent studies have started to answer those questions.

Zepbound appears to work best when treatment is continued

One of the clearest findings from the maintenance research is that people who continue tirzepatide after losing weight tend to maintain their weight loss better than people who stop it. In the SURMOUNT-4 trial, continued treatment helped patients maintain their progress and continue improving, while stopping tirzepatide was associated with significant weight regain.

This supports something many clinicians already see in practice: obesity treatment often works more like long-term treatment for a chronic disease than a short-term fix. The body frequently pushes back after weight loss, and stopping treatment can make maintenance harder.

Lower-dose Zepbound may help with maintenance, but not as well as staying on the full effective dose

Newer maintenance data also suggest that some patients may be able to preserve much of their progress on a lower maintenance dose of Zepbound. In SURMOUNT-MAINTAIN, patients who stepped down to a lower dose still maintained a meaningful amount of their weight loss, but those who stayed on their maximum tolerated dose maintained the most.

That is important because it suggests maintenance may not have to look exactly the same for every patient. Some people may do best staying on their current effective dose, while others may be able to step down and still keep a meaningful amount of progress.

Switching from Zepbound to Foundayo may help preserve much of the weight loss, but some regain can still happen

The newer ATTAIN-MAINTAIN study looked at what happens when patients who had already lost weight on injectable incretin therapy switched to Foundayo, the oral form of orforglipron. The study showed that switching to Foundayo helped patients maintain much more of their prior weight loss than switching to placebo.

That said, the switch did not appear to preserve weight loss as completely as simply staying on full-dose Zepbound. In other words, Foundayo may be a reasonable maintenance option for some patients who want an oral alternative, but it may involve more risk of partial regain than staying on the injectable medication that produced the original weight loss.

The switch may not work exactly the same for everyone

The early reporting on ATTAIN-MAINTAIN suggests that patients switching from semaglutide to Foundayo may have maintained more of their prior weight loss than patients switching from tirzepatide to Foundayo. That does not mean the switch from Zepbound cannot work. It means the response may depend on which medication a patient was on before, how much weight they lost, and how their body responds during maintenance.

What this means for patients

The overall message from these studies is fairly straightforward:

• continuing Zepbound is the strongest option for maintaining weight loss

• lowering the dose may still help preserve progress for some patients

• switching to Foundayo may be an option for patients who want a pill instead of an injection, but some regain may still occur

That is why maintenance planning matters so much. The question is not just how to lose weight. It is how to keep the health improvements that came with the weight loss.

Final thoughts

These studies reinforce an important point: maintenance is part of treatment. For many patients, the best long-term plan may involve continuing medication, adjusting dose thoughtfully, or choosing a maintenance strategy that balances convenience with effectiveness. The right approach depends on goals, side effects, affordability, and how well a patient is maintaining progress over time.